In this issue:
SC semaglutide for NASH
NAFLD and risk of diabetes
Sofosbuvir/velpatasvir 12 vs 6 weeks for acute HCV
TAF vs TDF in women of childbearing potential with HBV
Microbiota tryptophan metabolism in alcohol-induced liver injury
Glecaprevir/pibrentasvir for compensated cirrhosis
Glecaprevir/pibrentasvir after sofosbuvir + NS5A inhibitor failure
Interventions to improve HCV screening
Patient safety for HCV treated with glecaprevir/pibrentasvir
Metabolic and CV comorbidities in chronic HBV
Please login below to download this issue (PDF)